Table 2.
Response to generic rituximab in ITP patients
| Variable | n (%) or median (range) | 95% CIs |
|---|---|---|
| Time to response (median) | 28 days (21–51 days) | |
| Cumulative incidence of overall response | ||
| At day 20 of rituximab | 20 (30.61%) | [19.42–41.82%] |
| At day 30 of rituximab | 32 (51.72%) | [38.96–64.47%] |
| PR | 25 (37.88%) | |
| CR | 11 (16.67%) | |
| Time to relapse (days) | 1139 days | |
| (384-not reached) | ||
| Cummulative incidence of relapse | ||
| At 1 year | 10 (30.32%) | [14.73–45.92] |
| At 2 years | 11 (36.12%) | [19.52–52.71] |
| At 5 years | 17 (56.57%) | [38.4–74.74] |